


NATIONAL CLINICAL EFFECTI ENESS COMMITTEE



Management of the Initial and First Recurrence of Clostridium difficile Infection (CDI)

Guidance to be read in conjunction with National Clinical Guideline No. 3 Surveillance, Diagnosis and Management of Clostridium difficile Infection in Ireland (June 2014)



- For initial CDI oral fidaxomicin 200mg BD for 10 days may be an alternative to metronidazole, Grade C, or vancomycin, Grade A, in patients aged 16 yrs and older but only following discussion with a clinical microbiologist or infectious diseases consultant.
- Following discussion with a clinical microbiologist or infectious diseases consultant oral fidaxomicin may also be an option in the following situations:
 - o In patient/residents at high risk for recurrent CDI. Grade B
 - o In patient/resident with a first recurrence of CDI. Grade B
 - o Where concomitant antibiotics need to be used in patient/residents with CDI. Grade B

*Fidaxomicin has not been tested in pregnant or breastfeeding women or in patient/residents with a history of inflammatory bowel disease.

Further information

www.health.gov.ie/patient-safety/ncec www.hpsc.ie www.hse.ie

